title: A phase II study of gemcitabine and cisplatin combination as induction chemotherapy for untreated locally advanced cervical carcinoma.
abstract: BACKGROUND
  Cisplatin-based chemoradiation for locally advanced cervical carcinoma is now the standard of care for most patients with cervical carcinoma. However, induction chemotherapy followed by surgery, particularly with newer agents or combinations remains to be explored. This study was undertaken to evaluate the antitumor activity and toxicity of gemcitabine in combination with cisplatin for untreated locally advanced cervical carcinoma.
  
  
  METHODS
  Open-label, single center, phase II, non-randomized study of neoadjuvant gemcitabine plus cisplatin. Forty-one patients with histologic diagnosis of cervical carcinoma, with no previous treatment and staged as IB2 to IIIB, were treated with three 21-day courses of cisplatin 100 mg/m2 day I and gemcitabine 1000 mg/m2 days 1 and 8, followed by locoregional treatment with either surgery or concomitant chemoradiation. Response and toxicity were evaluated before each course and at the end of chemotherapy.
  
  
  RESULTS
  All patients were evaluated for toxicity and 40 for response. The overall objective response rate was 95% (95% confidence interval (CI): 88%-100%) being complete in 3 patients (7.5%) and partial in 35 (87.5%). A complete pathological response was found in 6 (26%) of the 23 patients that underwent surgery. Granulocytopenia grades 3-4 occurred in 13.8% and 3.4% of the courses, respectively, whereas non-hematological toxicity was mild.
  
  
  CONCLUSIONS
  Induction chemotherapy with the combination of gemcitabine and cisplatin is highly active for untreated cervical cancer patients and has an acceptable toxicity profile.
authors.affiliation: Department of Medical Oncology, Instituto Nacional de Cancerología, Mexico City, Mexico. alduenas@dfl.telmex.net.mx
authors.forename: A
authors.initials: A
authors.lastname: Dueñas-Gonzalez
authors.forename: C
authors.initials: C
authors.lastname: Lopez-Graniel
authors.forename: A
authors.initials: A
authors.lastname: Gonzalez
authors.forename: M
authors.initials: M
authors.lastname: Reyes
authors.forename: A
authors.initials: A
authors.lastname: Mota
authors.forename: D
authors.initials: D
authors.lastname: Muñoz
authors.forename: G
authors.initials: G
authors.lastname: Solorza
authors.forename: L M
authors.initials: LM
authors.lastname: Hinojosa
authors.forename: R
authors.initials: R
authors.lastname: Guadarrama
authors.forename: R
authors.initials: R
authors.lastname: Florentino
authors.forename: A
authors.initials: A
authors.lastname: Mohar
authors.forename: J
authors.initials: J
authors.lastname: Meléndez
authors.forename: V
authors.initials: V
authors.lastname: Maldonado
authors.forename: J
authors.initials: J
authors.lastname: Chanona
authors.forename: E
authors.initials: E
authors.lastname: Robles
authors.forename: J
authors.initials: J
authors.lastname: De la Garza
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D018196:Carcinoma, Adenosquamous / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D015996:Survival Rate; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D000093542:Gemcitabine
chemical_list: D003841:Deoxycytidine; D002945:Cisplatin; D000093542:Gemcitabine